Follow The Filings

BDX Becton Dickinson

Health Care, filed as BECTON DICKINSON & CO (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 6 managers in 2026 Q2, sold by 2

  • 1 Owner
  • #117
  • Max 13.3%
  • Master 0.23%
  • $1.1B
  • 1 add

In 2026 Q3 Greenhaven Associates added to Becton Dickinson.

Who owns this now

Largest portfolio weights among holders, up to 13.3% (Greenhaven Associates). Not free-float ownership.

  1. Greenhaven Associates Add 13.3%

Who owns BDX

Sorted by value, long equity only, as of 2026 Q3.

History
Greenhaven Associates 13.3%, was 9.9% Add +3.9% 5,904,730 $1.1B History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BDX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BDX insider trades
  • None no insider bought on the open market
  • $653K sold by 2 insiders outside a trading plan
  • $2.1M sold by 3 insiders under 10b5-1 plans
  1. Michael Feld EVP, Chief Revenue Officer
    Planned sale
    $15K 76 shares at $198.13 0.4% of stake
    Traded Oct 26 Filed Oct 27
    ↗
  2. Michael Feld EVP, Chief Revenue Officer
    Planned sale
    $14K 76 shares at $183.70 0.4% of stake
    Traded Sep 28 Filed Sep 29
    ↗
  3. Michael Feld EVP, Chief Revenue Officer
    Planned sale
    $31K 165 shares at $188.49 0.8% of stake
    Traded Aug 26 Filed Aug 27
    ↗
  4. Thomas E Polen Jr. CEO
    Planned sale
    $768K 4,152 shares at $185.00 3.6% of stake
    Traded Aug 13 Filed Aug 14
    ↗
  5. Roland Goette EVP and President, EMEA
    Sale
    $441K 2,438 shares at $180.84 14% of stake
    Traded Aug 11 Filed Aug 12
    ↗
  6. Michael Feld EVP, Chief Revenue Officer
    Planned sale
    $12K 75 shares at $157.13 0.4% of stake
    Traded Jul 27 Filed Jul 28
    ↗
  7. Michael Feld EVP, Chief Revenue Officer
    Planned sale
    $11K 75 shares at $152.80 0.4% of stake
    Traded Jun 26 Filed Jun 26
    ↗
  8. Michael David Garrison EVP & Pres Med.Essntl&BioPharm
    Planned sale
    $160K 1,100 shares at $145.66 7.7% of stake
    Traded Jun 24 Filed Jun 25
    ↗
  9. Michael David Garrison EVP & Pres Med.Essntl&BioPharm
    Planned sale
    $167K 1,100 shares at $151.48 7.2% of stake
    Traded Jun 10 Filed Jun 11
    ↗
  10. Thomas E Polen Jr. CEO
    Planned sale
    $405K 2,764 shares at $146.35 2.4% of stake
    Traded Jun 1 Filed Jun 3
    ↗
  11. Michael Feld EVP, Chief Revenue Officer
    Planned sale
    $11K 75 shares at $147.35 0.4% of stake
    Traded May 26 Filed May 27
    ↗
  12. Michael Feld EVP, Chief Revenue Officer
    Planned sale
    $11K 74 shares at $151.94 0.3% of stake
    Traded Apr 27 Filed Apr 28
    ↗
  13. Michael Feld EVP, Chief Revenue Officer
    Planned sale
    $12K 75 shares at $156.83 0.4% of stake
    Traded Mar 26 Filed Mar 27
    ↗
  14. Michael Feld EVP, Chief Revenue Officer
    Planned sale
    $14K 75 shares at $181.84 0.4% of stake
    Traded Feb 26 Filed Feb 27
    ↗
  15. Bertram L Scott Director
    Sale
    $174K 953 shares at $182.61 2.5% of stake
    Traded Feb 18 Filed Feb 18
    ↗

Also filed in the last 12 months, not counted as buying or selling: 36 stock grants, 14 share withholdings for taxes, 3 sales back to the company, and 3 option exercises.

Congress

8 members of Congress traded BDX in the last three years: 7 buys and 7 sales. 11 members listed it in 2025 annual reports.

All Congress trades
  1. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  2. Thomas H. Kean, Jr. R-NJ-7 Sell $1K–$15K May 21 filed Jun 18
  3. Kevin Hern R-OK-1Joint Sell $15K–$50K Mar 17 filed Apr 3
  4. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Jun 24, 2025 filed Aug 13, 2025
  5. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Jun 17, 2025 filed Aug 13, 2025
  6. Thomas H. Kean, Jr. R-NJ-7 Buy $1K–$15K May 13, 2025 filed Jun 17, 2025

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 7.01 Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
424B2 Filing Doc
8-K 8.01,9.01 Filing Doc
424B2 Filing Doc
8-K 2.02,9.01 Filing Doc
8-K/A 5.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.03,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $19.37B $20.18B $21.84B
Gross profit * $8.17B $9.12B $9.92B
Gross margin * 42.2% 45.2% 45.4%
Net income $1.48B $1.7B $1.68B
Net margin * 7.7% 8.4% 7.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $8.68B $10.47B $9.26B
Total non-current assets * $44.1B $46.82B $46.07B
Total assets $52.78B $57.29B $55.32B
Total current liabilities $6.64B $8.96B $8.31B
Total equity $25.8B $25.89B $25.39B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from investing — — -$818M
Cash from financing — — -$3.62B
Net change in cash $0.322B $0.375B -$1B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.